Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
MIST Stock Chart & Stats
$2.02
-$0.02(-0.90%)
At close: 4:00 PM EST
$2.02
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$0.77 - $3.06
Previous CloseN/A
Volume143.50K
Average Volume (3M)2.46M
Market Cap
$237.69M
Enterprise Value$158.83M
Total Cash (Recent Filing)$105.96M
Total Debt (Recent Filing)$58.38M
Price to Earnings (P/E)―
Beta2.69
Next Earnings
May 18, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding117,667,274
10 Day Avg. Volume3,579,700
30 Day Avg. Volume2,464,332
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)4.06
Price to Sales (P/S)109.60
P/FCF Ratio-3.43
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue102.73
Enterprise Value/Gross Profit106.81
Enterprise Value/Ebitda-2.64
Forecast
1Y Price Target
$7.33Price Target Upside262.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$53.55M
Bulls Say, Bears Say
Bulls Say
Clinical Profile And Unmet NeedCardamyst demonstrated meaningful efficacy with a favorable safety and tolerability profile and no expected branded competition, supporting potential for a successful commercial launch as a noninvasive alternative.
Commercial Execution And Early UptakeA national sales force is fully deployed and early prescriptions have been filled across key prescriber segments, indicating a functioning commercial infrastructure and initial market demand.
Payer Access ProgressThe Express Scripts agreement shifts the product from exception-based reimbursement into contracted access, creating a pathway for other major payers to follow and improve prescription fills.
Bears Say
Competitive UncertaintyWidespread availability of catheter ablation and oral therapies raises questions about the available market for a new therapy in paroxysmal supraventricular tachycardia, which could limit adoption.
Financial Pressure From Launch CostsCommercial launch preparations have driven higher operating expenses and resulted in a quarterly net loss, increasing financial pressure while payer coverage expands.
Reimbursement BottleneckPrior authorizations and payer controls are creating a bottleneck that slows conversion of prescriptions into filled claims, suppressing revenue despite written prescriptions.
Milestone Pharmaceuticals News
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $0.77 and its highest was $3.06 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Milestone Pharmaceuticals’s market cap is $237.69M.
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is May 18, 2026 which is in 35 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on Mar 20, 2026. The company reported -$0.16 earnings per share for the quarter, the consensus estimate of -$0.16 by $0.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is 0.17.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 117,667,274 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, expectations of -$0.16. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Currently, no hedge funds are holding shares in MIST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (262.87% Upside)
$7.33 (262.87% Upside)
Blogger Sentiment
Neutral
MIST Sentiment 50%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.2%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
169.33%
12-Months-Change
Fundamentals
Return on Equity
-656.82%
Trailing 12-Months
Asset Growth
50.41%
Trailing 12-Months
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
MIST Earnings Call
Q4 2026
0:00 / 0:00
MIST Stock 12 Month Forecast
Average Price Target
$7.33
▲(262.87% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Seres Therapeutics
―
Avalo Therapeutics
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
1.36% Insiders
0.09% Mutual Funds
16.54% Other Institutional Investors
80.19% Public Companies and
Individual Investors